Business Monitor International


Cambodia Pharmaceuticals & Healthcare Report

Published 11 April 2014

  • 65 pages
  • Instant access to your report online and PDF format through your account library
  • Includes 3 free updated quarterly reports
 
$1,295.00
Cambodia Pharmaceuticals & Healthcare Report

BMI View: Low health and pharmaceutical expenditures will continue to limit the attractiveness of the pharmaceutical market in Cambodia. Given such a profile, the country will present more commercial benefits to companies dealing with inexpensive generic drugs and over - the - counter products than innovative pharmaceuticals.

Headline Expenditure Projections

  • Pharmaceuticals: KHR828.7bn (US$210mn) in 2013 to KHR921.9bn (US$230mn) in 2014; +11.2% in local currency terms and +11.8% in US dollar terms.

  • Healthcare: KHR3,396.9bn (US$850mn) in 2013 to KHR3,639.9bn (US$910mn) in 2014; +7.2% in local currency terms and +7.7% in US dollar terms.

Risk/Reward Rating: Cambodia's Pharmaceutical Risk/Reward Rating (RRR) score for Q214 is 32.4 out of the maximum 100 in our newly improved RRR system. The country scored below average for almost all indicators and sub-indicators including overall market expenditure, sector value growth and pensionable population. Consequently, with this low score, Cambodia ranks second-to-last out of the 19 key markets in Asia Pacific, ahead of Myanmar.

Key Trends And Developments

  • In March 2014, France's Institut Pasteur du Cambodge opened a new facility in Cambodia to set up a regional research platform in Asia. Through the launch, the company is seeking to focus its research on infectious diseases in the region. The new facility will be used to train Cambodian and foreign researchers working on emerging or re-emerging infectious diseases, including encephalitis, dengue, chikungunya, avian influenza, or H5N1 and malaria among others.

In January 2014, Japan-based JGC Corporation started construction of a hospital in Phnom Penh, Cambodia. The hospital will entail an investment of JPY3.5bn (US$0.03bn) and incorporate Japanese medical technology and hospitality. It will be managed by a Cambodian subsidiary company in which JCG has around a 52% stake, public-private investment fund INCJ will have a 46% interest, while Kitahara Medical...

Table of Contents

BMI Industry View
7
SWOT
9
Industry Forecast
11
Pharmaceutical Market Forecast
11
Table: Cambodia Pharmaceutical Sales Indicators, 2009-2017
12
Healthcare Market Forecast
13
Table: Healthcare Expenditure Indicators, 2009-2017
14
Table: Healthcare Governmental Indicators, 2009-2017
15
Table: Healthcare Private Indicators 2009-2017
15
Pharmaceutical Trade Forecast
16
Table: Pharmaceutical Trade Indicators, 2009-2017
17
Key Risks To BMI's Forecast Scenario
18
Industry Risk Reward Ratings
19
Asia Pacific Risk
Asia Pacific Risk
Cambodia Risk
Cambodia Risk
Rewards
25
Risks
26
Market Overview
27
Industry Trends And Developments
29
Epidemiology
29
Healthcare Sector
30
Health Insurance
32
Research & Development
33
Clinical Trials
33
Regulatory Development
34
Regulatory Regime
34
Intellectual Property Issues
34
Counterfeit Medicines
35
Pricing And Reimbursement
38
Competitive Landscape
39
Pharmaceutical Sector
39
Company Developments
41
Pharmaceutical Wholesale
42
Pharmaceutical Retail
42
Company Profile
44
PharmaProduct Manufacturing (PPM)
44
Cambodia Pharmaceutical Enterprise
47
Sanofi
49
Pfizer
52
Demographic Forecast
54
Demographic Outlook - Cambodia
54
Table: Cambodia's Population By Age Group, 1990-2020 ('000)
55
Table: Cambodia's Population By Age Group, 1990-2020 (% of total)
56
Table: Cambodia's Key Population Ratios, 1990-2020
57
Table: Cambodia's Rural And Urban Population, 1990-2020
57
Glossary
58
Methodology
60
Pharmaceutical Expenditure Forecast Model
60
Healthcare Expenditure Forecast Model
60
Notes On Methodology
61
Risk
Risk
Ratings Overview
63
Table: Pharmaceutical Risk
Table: Pharmaceutical Risk
Indicator Weightings
64

The Cambodia Pharmaceuticals & Healthcare Report features Business Monitor International (BMI)'s forecasts for drugs and healthcare expenditure and imports and exports, focusing on the growth outlook for the prescription, OTC, patented drugs and generics market segments.

BMI's Cambodia Pharmaceuticals & Healthcare Report provides industry professionals, strategists, company executives, investors, analysts and sales/marketing heads with independent forecasts and competitive intelligence on the Cambodian pharmaceutical and healthcare industry.

Key Benefits

  • Benchmark BMI's independent pharmaceutical and healthcare industry forecasts for Cambodia to test other views - a key input for successful budgeting and strategic business planning in the Cambodian pharmaceutical and healthcare market.
  • Target business opportunities and risks in the Cambodian pharmaceutical and healthcare sector through our reviews of latest industry trends, regulatory changes and major deals, projects and investments in Cambodia.
  • Assess the activities, strategy and market position of your competitors, partners and clients via our Company Profiles (inc. SWOTs, KPIs and latest activity) and Competitive Landscape Tables.

Coverage

BMI Industry View & Industry SWOT

An at-a-glance perspective on latest regulatory developments, key forecast indicators and major corporate developments, covering the prescription, OTC and generics markets. The SWOT outlines strategic factors which affect BMI's forecast analysis, and taken together with BMI's political, economic and business environment SWOTS, it gives a complete overview of market climate.

Market Summary

Snapshot of key market characteristics, including total size of pharmaceuticals and healthcare segments, growth drivers, leading therapeutic areas and the competitive landscape.

Regulatory Regime

Details of the industry regulatory framework and key legislation covering the licensing of new products/services, pricing and reimbursements, intellectual property, taxation and advertising, as well as an analysis of the overall regulatory burden.

Industry Developments

Focus on government healthcare reforms, epidemiological trends, company M&As, product launches, market entries, FDI activity, R&D, biotechnology, clinical trials and supply chain issues.

BMI Industry Forecasts

Forecasts to end-2018 for all key industry indicators (see list below) supported by explicit assumptions, plus analysis of key downside risks to the main forecast, including:

Healthcare: Total healthcare expenditure (US$bn), healthcare expenditure (% of GDP), healthcare expenditure per capita (US$), hospital beds (per `000 population), doctors (per `000 population), birth and mortality rate (per `000 population)

Pharmaceutical market: Drug expenditure (US$bn), drug expenditure (% of GDP), drug expenditure per capita (US$)

Patented drug market: Prescription drug sales (US$bn), prescription sales (% of total sales), sales broken down by 14 therapeutic areas (cardiovascular, anti-infectives etc.)

Generic drug market: Generic product sales (US$bn), generic sales (% of total sales)

OTC drug market: OTC sales (US$bn), OTC sales (% of total sales), sales broken down by product types (analgesics, skin treatments, vitamins and minerals etc.)

Medical Devices: Medical device sales (US$bn), medical device sales (% of total healthcare market)

Macroeconomic Forecasts: Nominal and real GDP, % real GDP growth, % private consumption growth, % industrial output growth, % consumer price index, % GDP price deflator, exports, imports, trade balance, current account balance, foreign direct investment, exchange rate against US$, government expenditure, external debt.

Competitive Landscape

The competitive landscape section provides comparative company analyses and rankings by US$ sales and % share of total sales - for the total pharmaceutical sector, as well as the OTC, generics, and distribution sub-sectors.

Company Profiles

Examines the competitive positioning and short- to medium-term business strategies of key industry players. Strategy is examined within the context of BMI's industry forecasts, our macroeconomic views and our understanding of the wider competitive landscape to generate Company SWOT analyses. The latest financial and operating statistics and key company developments are also incorporated within the company profiles, enabling a full evaluation of recent company performance and future growth prospects.

secure
Benefit from discounts when you add multiple products to your basket
2 Products SAVE 10%
3 Products SAVE 15%
4 Products SAVE 20%
5 Products SAVE 25%
6 Products SAVE 30%
7 - 20 Products SAVE 35%
21 Products or more SAVE 40%

Testimonials

'An essential, multi-faceted research tool. BMI’s thorough understanding of the major market players enables an informed – and informative – review of the sector’s actual performance, together with useful insights into current industry issues, which are topped-off with detailed and invaluable forecasts of industry and macroeconomic trends.’

Senior Research Analyst, ABC International Bank plc